[HTML][HTML] The mechanism of HMGB1 secretion and release

R Chen, R Kang, D Tang - Experimental & molecular medicine, 2022 - nature.com
High mobility group box 1 (HMGB1) is a nonhistone nuclear protein that has multiple
functions according to its subcellular location. In the nucleus, HMGB1 is a DNA chaperone …

[HTML][HTML] From conventional to precision therapy in canine mammary cancer: a comprehensive review

G Valdivia, Á Alonso-Diez, D Pérez-Alenza… - Frontiers in veterinary …, 2021 - frontiersin.org
Canine mammary tumors (CMTs) are the most common neoplasm in intact female dogs.
Canine mammary cancer (CMC) represents 50% of CMTs, and besides surgery, which is the …

Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway

J Zhou, Y Jiang, H Chen, Y Wu, L Zhang - Cell proliferation, 2020 - Wiley Online Library
Abstract Objectives Tanshinone I (Tan‐I) is one of the vital fatsoluble monomer components,
which extracted from Chinese medicinal herb Salvia miltiorrhiza Bunge. It has been shown …

Genomic and molecular characterization of esophageal squamous cell carcinoma

DC Lin, JJ Hao, Y Nagata, L Xu, L Shang, X Meng… - Nature …, 2014 - nature.com
Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide and particularly
common in certain regions of Asia. Here we report the whole-exome or targeted deep …

Components and regulation of nuclear transport processes

B Cautain, R Hill, N de Pedro, W Link - The FEBS journal, 2015 - Wiley Online Library
The spatial separation of DNA replication and gene transcription in the nucleus and protein
translation in the cytoplasm is a uniform principle of eukaryotic cells. This …

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

R Lapalombella, Q Sun, K Williams… - Blood, The Journal …, 2012 - ashpublications.org
The nuclear export protein XPO1 is overexpressed in cancer, leading to the cytoplasmic
mislocalization of multiple tumor suppressor proteins. Existing XPO1-targeting agents lack …

Nuclear localization signal-tagged systems: Relevant nuclear import principles in the context of current therapeutic design

R Goswami, A Gupta, O Bednova… - Chemical Society …, 2024 - pubs.rsc.org
Nuclear targeting of therapeutics provides a strategy for enhancing efficacy of molecules
active in the nucleus and minimizing off-target effects.'Active'nuclear-directed transport and …

First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors

AR Abdul Razak, M Mau-Soerensen… - Journal of Clinical …, 2016 - ascopubs.org
Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy
of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1) …

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

YT Tai, Y Landesman, C Acharya, Y Calle, MY Zhong… - Leukemia, 2014 - nature.com
The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic
target in human multiple myeloma (MM). Here we showed that chromosome region …

[HTML][HTML] Multiple myeloma therapy: emerging trends and challenges

D Dima, D Jiang, DJ Singh, M Hasipek, HS Shah… - Cancers, 2022 - mdpi.com
Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …